| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| April 29, 2026 | ±3.3% | +5.8% | under-priced |
| November 5, 2025 | ±2.9% | -6.0% | under-priced |
| July 30, 2025 | ±3.9% | +12.4% | under-priced |
| April 30, 2025 | ±3.0% | +1.1% | over-priced |
| October 30, 2024 | ±2.8% | +3.3% | under-priced |
| July 31, 2024 | ±2.8% | -10.6% | under-priced |
| April 24, 2024 | ±2.3% | -3.7% | under-priced |
| November 1, 2023 | ±1.9% | -6.6% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $9.83 | $39.6B | $1.2B |
| Q4 FY2025 | $-6.59 | $32.5B | $-776M |
| Q3 FY2025 | $1.62 | $32.6B | $194M |
| Q2 FY2025 | $4.51 | $32.4B | $543M |
Humana Inc. (HUM) reports in 91 days, with the next report estimated for September 12, 2026. Across the last 8 reports, options priced an average ±2.9% earnings move while the stock actually moved 6.2% on average — the market has tended to under-price HUM's earnings risk. Fundamentals into the print: EPS down 4.6% year-over-year, revenue up 23.5%. QuantLogix's live 5-factor engine currently reads HUM as a buy at 63/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →